<DOC>
	<DOC>NCT02765633</DOC>
	<brief_summary>The purpose of this study is to assess the PK/PD and safety profile of cangrelor in neonatal subjects at risk of thrombosis.</brief_summary>
	<brief_title>Cangrelor Neonatal PK/PD and Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Cangrelor</mesh_term>
	<criteria>Inclusion criteria: 1. Males and females with congenital heart disease, and ranging in age from birth through 28 days of life 2. Postoperative neonatal cardiac subjects with placement of systemictopulmonary artery palliative shunts, right ventricle to pulmonary artery palliative shunts, or ductus arteriosus stents who are at risk of thrombotic events after repair for structural congenital heart disease. 3. Written informed consent from a parent/legal guardian 4. Life expectancy of at least 15 days at study entry Subjects will be excluded from the study if any of the following exclusion criteria apply: 1. History of intracerebral bleed (confirmed by a US of the head prior to surgery), or cerebral arteriovenous malformation, or any prior bleed with neurological deficit 2. Gastrointestinal or urinary bleeding 3. Cerebrovascular accident or any cerebrovascular accident with a residual neurological deficit 4. Known congenital or acquired bleeding or clotting disorder 5. Weight less than 2.5 kg 6. Adjusted gestational age less than 37 weeks 7. Platelet count less than 100,000 cells/µL 8. Chest and/or mediastinal tube blood output of greater than 3 mL/kg/hr at the time of cangrelor administration 9. Subjects with evidence of severe hepatic or renal failure [aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than three times normal for age or total bilirubin greater than 20 mg/dL; creatinine greater than 2 times the normal upper limit] 10. Known allergy to cangrelor or known sensitivity to any component of cangrelor 11. Any condition that in the investigator's opinion would constitute a contraindication to participation in the study or cause inability to comply with the study requirements 12. Participation in another investigational therapeutic drug or investigational therapeutic device trial within 30 days of starting study 13. Subjects who have been receiving warfarin (Coumadin®) therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>28 Days</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>